Compendium of Cancer Genome Aberrations

Changes

HAEM5:Juvenile myelomonocytic leukaemia (view source)

Revision as of 14:29, 13 December 2023

1,032 bytes added ,  14:29, 13 December 2023
no edit summary
Line 4: Line 4:  
{{Under Construction}}
 
{{Under Construction}}
   −
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Juvenile Myelomonocytic Leukemia (JMML)]].
+
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Juvenile Myelomonocytic Leukemia (JMML)]].
 
}}</blockquote>
 
}}</blockquote>
 +
 +
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
 +
 
==Primary Author(s)*==
 
==Primary Author(s)*==
   Line 16: Line 19:  
__TOC__
 
__TOC__
   −
==Cancer Category/Type==
+
==Cancer Category / Type==
    
Myeloproliferative neoplasm
 
Myeloproliferative neoplasm
Line 128: Line 131:     
</blockquote>
 
</blockquote>
−
==Individual Region Genomic Gain/Loss/LOH==
+
==Individual Region Genomic Gain / Loss / LOH==
    
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
Line 213: Line 216:  
<br />
 
<br />
 
</blockquote>
 
</blockquote>
−
==Gene Mutations (SNV/INDEL)==
+
==Gene Mutations (SNV / INDEL)==
    
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
Line 323: Line 326:  
==Genetic Diagnostic Testing Methods==
 
==Genetic Diagnostic Testing Methods==
   −
Put your text here
      +
*Clinical and hematologic features:
 +
**Peripheral blood monocyte count <u>></u> 1 x 10<sup>9</sup>/L (present in most cases)
 +
**Splenomegaly (present in >95 % cases at presentation)
 +
**Blast percentage in peripheral blood and bone marrow < 20%
 +
**Absence of ''BCR::ABL1''
 +
*Genetic studies (one finding required):
 +
**Somatic mutation in ''PTPN11, KRAS, NRAS,'' or ''RRAS''
 +
**Germline ''NF1'' mutation and loss of heterozygosity of ''NF1'' or clinical diagnosis of neurofibromatosis type 1
 +
**Germline ''CBL'' mutation and loss of heterozygosity of ''CBL''
 +
 +
 +
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Arber|first=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert P.|last4=Borowitz|first4=Michael J.|last5=Calvo|first5=Katherine R.|last6=Kvasnicka|first6=Hans-Michael|last7=Wang|first7=Sa A.|last8=Bagg|first8=Adam|last9=Barbui|first9=Tiziano|date=2022-09-15|title=International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data|url=https://pubmed.ncbi.nlm.nih.gov/35767897|journal=Blood|volume=140|issue=11|pages=1200–1228|doi=10.1182/blood.2022015850|issn=1528-0020|pmc=9479031|pmid=35767897}}</ref></blockquote>
 
==Familial Forms==
 
==Familial Forms==
   Line 347: Line 361:  
<nowiki>*</nowiki>''Citation of this Page'': “Juvenile myelomonocytic leukaemia”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Juvenile_myelomonocytic_leukaemia</nowiki>.
 
<nowiki>*</nowiki>''Citation of this Page'': “Juvenile myelomonocytic leukaemia”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Juvenile_myelomonocytic_leukaemia</nowiki>.
 
==Other Sections==
 
==Other Sections==
−
Diagnostic Testing Method
  −
  −
  −
  −
*Clinical and hematologic features:
  −
**Peripheral blood monocyte count <u>></u> 1 x 10<sup>9</sup>/L (present in most cases)
  −
**Splenomegaly (present in >95 % cases at presentation)
  −
**Blast percentage in peripheral blood and bone marrow < 20%
  −
**Absence of ''BCR::ABL1''
  −
*Genetic studies (one finding required):
  −
**Somatic mutation in ''PTPN11, KRAS, NRAS,'' or ''RRAS''
  −
**Germline ''NF1'' mutation and loss of heterozygosity of ''NF1'' or clinical diagnosis of neurofibromatosis type 1
  −
**Germline ''CBL'' mutation and loss of heterozygosity of ''CBL''
  −
  −
  −
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Arber|first=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert P.|last4=Borowitz|first4=Michael J.|last5=Calvo|first5=Katherine R.|last6=Kvasnicka|first6=Hans-Michael|last7=Wang|first7=Sa A.|last8=Bagg|first8=Adam|last9=Barbui|first9=Tiziano|date=2022-09-15|title=International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data|url=https://pubmed.ncbi.nlm.nih.gov/35767897|journal=Blood|volume=140|issue=11|pages=1200–1228|doi=10.1182/blood.2022015850|issn=1528-0020|pmc=9479031|pmid=35767897}}</ref></blockquote>
  −
   
Genetic Susceptibility
 
Genetic Susceptibility
  
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/12758...13756"